# MaxCyte, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/MaxCyte, Inc).

## Overview

MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family. It sells instruments, single-use processing assemblies and consumables, and licenses its platform to cell therapy developers through strategic partnership license (SPL) agreements that can also generate milestone and sales-based payments.

## Products & services

• ExPERT cell engineering platform and Flow Electroporation technology
• ATx, STx, GTx and VLx instruments
• Processing assemblies (PAs) and consumables
• Research and clinical licenses
• Assay services and other platform-related offerings

- **Instruments** (20%) — Capital equipment sold to cell therapy, biotech and research customers for cell engineering workflows.
- **Processing assemblies and consumables** (40%) — Single-use PAs, buffers, accessories and other recurring consumables used with ExPERT instruments.
- **Licenses** (25%) — Research, clinical and SPL license agreements that provide access to the platform and related rights.
- **Program-related revenue** (10%) — Milestone and sales-based payments under SPL partnerships tied to partner clinical and regulatory progress.
- **Services and other revenue** (5%) — Assay services and other smaller platform-related revenue streams.

- ExPERT platform for non-viral cell engineering
- ATx, STx, GTx and VLx electroporation instruments
- Single-use processing assemblies (PAs) and consumables
- Research and clinical platform licenses
- Assay services and related platform offerings

## Customers

MaxCyte sells to cell therapy developers, biopharmaceutical companies, and translational research institutions that need non-viral cell engineering tools. Its customer base includes 29 SPL partners, a majority of the top 25 global pharmaceutical companies, hundreds of biotech companies, and academic and government research centers such as the NIH.

- **Cell therapy developers** (primary) — Buy instruments, PAs and licenses to engineer cells for preclinical, clinical and commercial programs.
- **Large biopharmaceutical companies** (primary) — Use the platform through licenses and partnerships to support internal cell therapy pipelines.
- **Biotechnology companies** (primary) — Purchase instruments and consumables for translational research and advancing pipeline programs.
- **Academic and government research institutions** (secondary) — Use the platform for discovery and translational research, supporting installed base growth.
- **SPL partners** (primary) — Strategic partners that generate milestone, annual license and sales-based payments as programs progress.

- Cell therapy developers buying instruments and PAs for R&D and clinical work
- Biopharma companies licensing the platform for non-viral cell engineering
- SPL partners that pay milestones as programs advance
- Academic and government labs using the platform for translational research
- Customers shifting from viral to non-viral approaches in cell therapy

## Geography

The company is headquartered in the United States and the disclosed excerpts do not provide a country revenue split. Its business is global in nature because its customer base includes U.S. and foreign biopharma, biotech, academic and government institutions, and its patent portfolio and SPL partnerships extend across major life-science markets.

- Headquartered in the United States
- Customer base spans U.S. and international life-science markets
- SPL partnerships and patents support global commercialization
- Revenue is driven by where cell therapy programs and research budgets are located
- No country-level revenue split was disclosed in the excerpts

## Strategy

MaxCyte is focused on expanding adoption of its non-viral cell engineering platform as cell therapy moves from discovery into clinical development and commercialization. Management is prioritizing sales and marketing, R&D, and product expansion while growing the installed base and increasing the share of customers under SPL agreements.

- **Expand SPL partnerships and installed base** (medium-term) — More SPL agreements can increase recurring license income and milestone opportunities as partner programs mature.
- **Drive recurring consumables and PA sales** (short-term) — Recurring use of PAs and consumables improves revenue durability versus one-time instrument sales.
- **Win share in non-viral cell engineering** (medium-term) — The shift away from viral approaches expands the addressable market for Flow Electroporation.

- Grow installed base of ExPERT instruments and recurring PAs
- Expand SPL partnerships to increase milestone and license revenue
- Capture demand from the shift away from viral to non-viral methods
- Support customer progression from preclinical to commercial stages
- Invest in sales, marketing, R&D and product development

## Risks

Revenue is inherently lumpy because instrument sales, licenses and SPL milestones depend on customer program timing and clinical/regulatory progress. The company also remains loss-making and cash-burning, so execution on growth, product adoption and capital discipline matters for funding needs and valuation.

- **Program-related revenue variability** [high] — SPL milestone and sales-based payments depend on partner achievements that are outside the company's control.
- **Customer pipeline timing risk** [high] — Instrument, PA and license demand rises only as customers move programs into later-stage development.
- **Operating losses and liquidity pressure** [high] — The company expects near-term operating losses while investing in growth, which can require additional capital over time.
- **Technology adoption and competitive risk** [medium] — Cell therapy customers may choose competing non-viral or viral workflows if performance, cost or validation is better.

- Milestone revenue can swing with partner clinical and regulatory timing
- Customer program delays can defer instrument, PA and license sales
- Losses and negative cash flow require continued funding discipline
- Competition from alternative cell engineering technologies may pressure adoption
- Dependence on a concentrated set of biopharma and SPL partners creates customer risk

## Accounting

Revenue recognition is a key accounting issue because MaxCyte combines point-in-time instrument and consumable sales with license revenue and performance-based SPL milestones that can be recognized only when contractual conditions are met. Quarterly results can be volatile because milestone timing is uncertain, and management also relies on judgment for goodwill, acquired technology valuation and other estimates tied to future growth assumptions.

- **Revenue recognition for SPL agreements** — Drives quarter-to-quarter volatility in program-related revenue
- **Goodwill impairment** — Could create non-cash impairment expense
- **Business combination accounting for developed technology** — Affects intangible asset balances and future amortization
- **Critical estimates and judgments** — Can materially affect reported earnings and balance sheet values

- SPL milestones create timing-sensitive revenue recognition
- Instrument and PA sales are recognized when control transfers
- Quarterly revenue can fluctuate sharply with partner progress
- Goodwill impairment depends on future growth and discount-rate assumptions
- Acquired technology valuation affects intangible assets and amortization

---

*Last updated: 2026-09-24T11:41:35.947988+00:00*